<DOC>
	<DOCNO>NCT00440336</DOCNO>
	<brief_summary>WHAT IS THIS STUDY ABOUT ? Glaucoma ocular hypertension chronic eye diseases damage optic nerve lead vision loss blindness . The optic nerve act like electric cable million wire . This nerve responsible carrying image eye brain . The way glaucoma ocular hypertension cause blindness depend many factor , important factor increase pressure inside eye ( intraocular pressure ) . There cure glaucoma ocular hypertension . However , lower pressure inside eye show slow progression disease . Intraocular pressure lower glaucoma medication , laser treatment , surgery . You open angle glaucoma , pseudoexfoliative glaucoma , ocular hypertension . Researchers want find 2 drug call Cosopt ( dorzolamide hydrochloride timolol maleate ) Xalatan ( latanoprost ) help people condition . Cosopt Xalatan eye drop approve U.S. Food Drug Administration ( FDA ) reduce intraocular pressure people open angle glaucoma ocular hypertension . The study doctor laser procedure call Selective Laser Trabeculoplasty ( SLT ) people study help low intraocular pressure . The FDA approve SLT treat open angle glaucoma ocular hypertension . Then study doctor ask participant use either Cosopt Xalatan , intraocular pressure still high 4 6 week SLT procedure . The study doctor want see 2 study drug ( Cosopt Xalatan ) well reduce intraocular pressure SLT . It plan 30 people glaucoma ocular hypertension least 18 year old study . Out participant whose intraocular pressure still high SLT , half use Cosopt half use Xalatan . You study SLT use Cosopt Xalatan .</brief_summary>
	<brief_title>Comparison Efficacy Two Groups Glaucoma Drops ( Xalatan vs.Cosopt ) Reducing Eye Pressure Following Laser ( SLT ) Treatment Management Glaucoma .</brief_title>
	<detailed_description>Introduction Selective Laser Trabeculoplasty show relatively safe effective treatment modality lower IOP various form open-angle glaucoma ( Latina et al ) . It lower IOP increase aqueous outflow effect cellular level possibly either ( 1 ) migration phagocytosis trabecular meshwork debris macrophage ( 2 ) stimulate proliferation healthy trabecular endothelial cell . Cases ’ achieve target IOP follow SLT therapy need additional treatment form topical medication . Conventionally common topical antiglaucoma medication treat glaucoma SLT therapy either suppress aqueous secretion ( B-blockers carbonic anhydrase inhibitor ) enhance uveoscleral aqueous outflow ( Prostaglandin analogue ) . Since Selective Laser Trabeculoplasty act outflow pathway , additional IOP reduction achieve effectively class drug act different pathway ; aqueous secretion aqueous suppressant like Cosopt . In contrast drug act outflow pathway like prostaglandin analogue ( Xalatan etc ) possibly less additive reduce IOP SLT since SLT also effect pathway- outflow pathway . Previous study ( Fechtner et al . J Ocul Pharmacol Ther . 2005 Jun ; 21 ( 3 ) :242-9 Fechtner et al . Acta Ophthalmol Scand . 2004 Feb ; 82 ( 1 ) :42-8 . ) show equal efficacy Cosopt Latanoprost reduce IOP treatment glaucoma . But knowledge , long term prospective study evaluate aqueous suppressant ( Cosopt ) prostaglandin analogue respect comparative efficacy treatment uncontrolled glaucoma status post SLT therapy . OBJECTIVE The primary objective study compare IOP lower efficacy aqueous suppressant ( Cosopt ) prostaglandin analogue ( Xalatan ) use status post SLT management Open Angle Glaucoma Ocular Hypertension . INCLUSION CRITERIA 1 . Adult subject either sex , race , eighteen year age old . 2 Diagnosis : Primary Open Angle Glaucoma , Pseudoexfoliation Glaucoma , Ocular Hypertension . 3 . Mild moderate glaucoma : Pattern standard deviation ( PSD ) ; 1DB less 6 DB Humphrey Visual Field . 3 . Subject may ; - A newly diagnose glaucoma - A pre-existing glaucoma two topical antiglaucoma medication . 3 On systemic medication know increase IOP ( e.g . steroid ) 4 Visual acuity equal well 20/200 study eye 5 . IOP le 35 mm Hg study eye 6 No previous intraocular surgery within last 6 month , except laser PI great 3 month ago . EXCLUSION CRITERIA Pigmentary OAG , Proliferative diabetic retinopathy , History chronic recurrent severe inflammatory eye disease ( i.e . scleritis , uveitis , herpes keratitis ) , know allergy COSOPT Prostaglandin Analogues , Chronic Obstructive Airways Disease ( COPD ) , sinus bradycardia ( heart rate &lt; 60 beat per minute ) , second third-degree atrioventricular block , overt cardiac failure . Pregnant nursing mother . STUDY DESIGN : Single site , unmasked , prospective , randomize study STUDY PROCEDURE Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Screening Phase SLT Treatment Phase Safety check 2 week SLT RANDOMIZATION 4 6 week SLT Follow visit , 6 week randomization Last Visit 3 month randomization Determine eligibility routine eye exam include IOP check Goldmann applanation tonometer , Gonioscopy , fundus exam , Humphrey Visual Field ( HVF do within last 6 month ) . Subjects , fulfill eligibility criterion give consent participate study , schedule SLT . All eligible subject receive SLT . Pre-existing glaucoma case already antiglaucoma medication discontinue antiglaucoma medication since day SLT treatment drop next 4 6 week . Similarly newly diagnose glaucoma antiglaucoma medication . next 4 6 week . Each subject IOP check 2 week SLT treatment . It do rule unusual IOP spike follow SLT . Each subject routine eye exam include IOP check visit . The subject uncontrolled IOP despite SLT therapy randomize receive either COSOPT Prostaglandin analogue ( XALATAN ) . IOP check routine eye exam . IOP check , routine eye exam include fundus exam Humphrey Visual Field .  If IOP uncontrolled visit 5 , step drug therapy initiate base follow protocol : 1 . For patient Cosopt group randomization . Sequence additional medication follow : First Step : Alphagan ( Brimonidine ) Second Step : Prostaglandin Analogues 2 . For patient Xalatan group randomization . Sequence additional medication follow : First Step : Alphagan ( Brimonidine ) Second Step : Dorzolamide ( Trusopt ) Note : IOP measure use Goldmann Applanation Tonometer 8 AM 10 AM visit : Visit I , Visit IV , Visit V Visit VI . A ± 30 minute window allow measurement recording . IOP measurement Visit II ( SLT treatment phase ) Visit III ( safety check ) do random time . Duration Study Participation ; Subjects eligible participate study shall enrol approximately 6 month . References ; Fechtner RD , McCarroll KA , Lines CR , Adamsons IA . Efficacy dorzolamide/timolol fix combination versus latanoprost treatment ocular hypertension glaucoma : combine analysis pool data two large randomize observer patient-masked studies.J Ocul Pharmacol Ther . 2005 Jun ; 21 ( 3 ) :242-9 Fechtner RD , Airaksinen PJ , Getson AJ , Lines CR , Adamsons IA ; COSOPT versus XALATAN Study Groups . Efficacy tolerability dorzolamide 2 % /timolol 0.5 % combination ( COSOPT ) versus 0.005 % ( XALATAN ) treatment ocular hypertension glaucoma : result two randomized clinical trial . Acta Ophthalmol Scand . 2004 Feb ; 82 ( 1 ) :42-8 . Latina MA , Tumbocon Ja . SLT : new treatment option open-angle glaucoma . Curr Opin Ophthalmol 2002 ; 13:94-6</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>1 . Adult subject either sex , race , eighteen year age old . 2 . Diagnosis : Primary Open Angle Glaucoma , Pseudoexfoliation Glaucoma , Ocular Hypertension . 3 . Mild moderate glaucoma : Pattern standard deviation ( PSD ) ; 1DB less 6 DB Humphrey Visual Field . 4 . Subject may : A newly diagnose glaucoma A preexisting glaucoma two topical antiglaucoma medication . 5 . On systemic medication know increase IOP ( e.g . steroid ) 6 . Visual acuity equal well 20/200 study eye 7 . IOP le 35 mm Hg study eye 8 . No previous intraocular surgery within last 6 month , except laser PI great 3 month ago . 1 . Pigmentary OAG , 2 . Proliferative diabetic retinopathy , 3 . History chronic recurrent severe inflammatory eye disease ( i.e . scleritis , uveitis , herpes keratitis ) , 4 . Known allergy COSOPT Prostaglandin Analogues , 5 . Chronic Obstructive Airways Disease ( COPD ) , 6 . Sinus bradycardia ( heart rate &lt; 60 beat per minute ) , 7 . Second thirddegree atrioventricular block , 8 . Overt cardiac failure . 9 . Pregnant nursing mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>IOP</keyword>
	<keyword>SLT</keyword>
	<keyword>Laser</keyword>
	<keyword>Cosopt</keyword>
</DOC>